Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Curr Opin Obstet Gynecol ; 33(2): 100-105, 2021 04 01.
Article in English | MEDLINE | ID: mdl-33620888

ABSTRACT

PURPOSE OF REVIEW: The transfer of mosaic embryos during an IVF procedure is becoming more common. There is limited information regarding the outcomes for such transfers, making it difficult to establish best practices for prenatal counseling of patients considering transfer of mosaic embryos. In addition, genetic counseling may be delivered by different providers in the preimplantation and pregnancy timeframes which can contribute to inconsistent information. RECENT FINDINGS: There are many types of aneuploid results from preimplantation genetic testing for aneuploidy (PGT-A), with mosaicism being a possibility. Recent studies have reported normal prenatal diagnostic results, pregnancy and birth outcomes with mosaic embryo transfers. Reproductive and prenatal society guidelines recommend diagnostic testing in pregnancy following a mosaic result by PGT-A. Prenatal genetic counseling providers should consider the available information from the PGT-A result, emphasizing the benefits and limitations of each available prenatal test in detecting the fetal chromosome complement. SUMMARY: While transfer of mosaic embryos can allow couples without euploid embryos to have a chance of a viable pregnancy, further studies are necessary to better guide this decision-making. In addition, better coordination between reproductive providers and prenatal providers could improve prenatal care.


Subject(s)
Genetic Counseling , Preimplantation Diagnosis , Aneuploidy , Blastocyst , Embryo Transfer , Female , Fertilization in Vitro , Genetic Testing , Humans , Pregnancy
2.
Am J Med Genet A ; 167A(10): 2463-9, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26219535

ABSTRACT

We report on a 6-month-old girl with two apparent cell lines; one with trisomy 21, and the other with paternal genome-wide uniparental isodisomy (GWUPiD), identified using single nucleotide polymorphism (SNP) based microarray and microsatellite analysis of polymorphic loci. The patient has Beckwith-Wiedemann syndrome (BWS) due to paternal uniparental disomy (UPD) at chromosome location 11p15 (UPD 11p15), which was confirmed through methylation analysis. Hyperinsulinemic hypoglycemia is present, which is associated with paternal UPD 11p15.5; and she likely has medullary nephrocalcinosis, which is associated with paternal UPD 20, although this was not biochemically confirmed. Angelman syndrome (AS) analysis was negative but this testing is not completely informative; she has no specific features of AS. Clinical features of this patient include: dysmorphic features consistent with trisomy 21, tetralogy of Fallot, hemihypertrophy, swirled skin hyperpigmentation, hepatoblastoma, and Wilms tumor. Her karyotype is 47,XX,+21[19]/46,XX[4], and microarray results suggest that the cell line with trisomy 21 is biparentally inherited and represents 40-50% of the genomic material in the tested specimen. The difference in the level of cytogenetically detected mosaicism versus the level of mosaicism observed via microarray analysis is likely caused by differences in the test methodologies. While a handful of cases of mosaic paternal GWUPiD have been reported, this patient is the only reported case that also involves trisomy 21. Other GWUPiD patients have presented with features associated with multiple imprinted regions, as does our patient.


Subject(s)
Beckwith-Wiedemann Syndrome/genetics , Congenital Hyperinsulinism/genetics , Down Syndrome/genetics , Genomic Imprinting , Mosaicism , Uniparental Disomy/genetics , Beckwith-Wiedemann Syndrome/diagnosis , Beckwith-Wiedemann Syndrome/pathology , Chromosomes, Human, Pair 11 , Comparative Genomic Hybridization , Congenital Hyperinsulinism/diagnosis , Congenital Hyperinsulinism/pathology , DNA Methylation , Down Syndrome/diagnosis , Down Syndrome/pathology , Female , Genome, Human , Humans , Infant , Karyotype , Polymorphism, Single Nucleotide , Uniparental Disomy/diagnosis , Uniparental Disomy/pathology
3.
BMC Health Serv Res ; 11: 294, 2011 Nov 02.
Article in English | MEDLINE | ID: mdl-22047175

ABSTRACT

BACKGROUND: Genetic testing is increasingly used as a tool throughout the health care system. In 2011 the number of clinically available genetic tests is approaching 2,000, and wide variation exists between these tests in their sensitivity, specificity, and clinical implications, as well as the potential for discrimination based on the results. DISCUSSION: As health care systems increasingly implement electronic medical record systems (EMRs) they must carefully consider how to use information from this wide spectrum of genetic tests, with whom to share information, and how to provide decision support for clinicians to properly interpret the information. Although some characteristics of genetic tests overlap with other medical test results, there are reasons to make genetic test results widely available to health care providers and counterbalancing reasons to restrict access to these test results to honor patient preferences, and avoid distracting or confusing clinicians with irrelevant but complex information. Electronic medical records can facilitate and provide reasonable restrictions on access to genetic test results and deliver education and decision support tools to guide appropriate interpretation and use. SUMMARY: This paper will serve to review some of the key characteristics of genetic tests as they relate to design of access control and decision support of genetic test information in the EMR, emphasizing the clear need for health information technology (HIT) to be part of optimal implementation of genetic medicine, and the importance of understanding key characteristics of genetic tests when designing HIT applications.


Subject(s)
Decision Support Systems, Clinical , Electronic Health Records , Genetic Privacy , Genetic Testing , Humans , Information Management , Practice Guidelines as Topic
4.
Case Rep Genet ; 2015: 131852, 2015.
Article in English | MEDLINE | ID: mdl-26064708

ABSTRACT

This case report concerns a 16-year-old girl with a 9.92 Mb, heterozygous interstitial chromosome deletion at 7q33-q35, identified using array comparative genomic hybridization. The patient has dysmorphic facial features, intellectual disability, recurrent infections, self-injurious behavior, obesity, and recent onset of hemihypertrophy. This patient has overlapping features with previously reported individuals who have similar deletions spanning the 7q32-q36 region. It has been difficult to describe an interstitial 7q deletion syndrome due to variations in the sizes and regions in the few patients reported in the literature. This case contributes to the further characterization of an interstitial distal 7q deletion syndrome.

5.
Case Rep Genet ; 2011: 306072, 2011.
Article in English | MEDLINE | ID: mdl-23074674

ABSTRACT

We report a 4-year-old girl of Mexican origins with a clinical diagnosis of Dubowitz syndrome who carries a de novo terminal deletion at the 14q32.33 locus identified by array comparative genomic hybridization (aCGH). Dubowitz syndrome is a rare condition characterized by a constellation of features including growth retardation, short stature, microcephaly, micrognathia, eczema, telecanthus, blepharophimosis, ptosis, epicanthal folds, broad nasal bridge, round-tipped nose, mild to moderate developmental delay, and high-pitched hoarse voice. This syndrome is thought to be autosomal recessive; however, the etiology has not been determined. This is the first report of this deletion in association with this phenotype; it is possible that this deletion may be causal for a Dubowitz phenocopy.

6.
Genet Test Mol Biomarkers ; 15(7-8): 517-23, 2011.
Article in English | MEDLINE | ID: mdl-21453058

ABSTRACT

PURPOSE: Cystic fibrosis (CF) carrier screening guidelines have been in place for almost a decade. The purpose of this study was to determine the current awareness by obstetricians of the existence and content of practice guidelines, the variety in practice regarding CF carrier screening, and the level of knowledge regarding CF genetics and screening result interpretation. We also explored potential barriers to offering screening and whether academic affiliation or type of practice influenced outcome. METHODS: An online survey program was used to deliver a questionnaire to obstetricians throughout the United States. One hundred fifty-six respondents participated, with 143 answering all questions in the survey. RESULTS: Although most obstetricians are aware of screening guidelines and have accurate knowledge about CF carrier screening, 12.3% were not aware of carrier screening guidelines, 17.7% were unable to interpret basic results, 16.5% experienced barriers to offering screening, and 43% lacked information regarding carrier rates, screening sensitivity, and residual risk. CONCLUSION: Most obstetricians offer CF carrier screening and will refer to genetic counseling services at times. However, we identified a deficiency of information in a concerning percentage of practitioners. This deficiency could be improved by targeted and readily accessible educational efforts, especially for obstetricians not affiliated with academia.


Subject(s)
Cystic Fibrosis/diagnosis , Genetic Carrier Screening , Genetic Testing , Gynecology , Obstetrics , Practice Guidelines as Topic , Cystic Fibrosis/genetics , Genetic Counseling , Health Care Surveys , Health Knowledge, Attitudes, Practice , Humans , Internet , Practice Patterns, Physicians' , Surveys and Questionnaires , United States
SELECTION OF CITATIONS
SEARCH DETAIL